treatmentchemotherapyinhibitorsThe article discusses research on the effectiveness of tyrosine kinase inhibitors such as gefitinib or erlotinib in the treatment of epidermal growth factor receptor (EGFR) mutation-positive lung cancer. It was shown that gefitinib is useful as a second-line treatment ...
availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has provided oncologists with a potentially confusing choice for the treatment of EGFR mutation-positive non-small-cell lung cancer. ...
The discovery of the association between EGFR mutations and the efficacy of EGFR tyrosine-kinase inhibitors (TKIs) has revolutionized the treatment paradigm for patients with non-small-cell lung cancer (NSCLC). Currently, third-generation EGFR TKIs, which are often characterized by potent central nerv...
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard of care for patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). Osimertinib, a mutant selective EGFR TKI, when used as initial therapy, results in median progression free survival (PFS)...
et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239–246 (2012). Article CAS PubMed Google Scholar Mok,...
S. et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J. Clin. Oncol. 36, 841–849 (2018). CAS PubMed Google Scholar Loibl, S. & Gianni, L. HER2-positive breast cancer. Lancet 389, 2415–2429 (2017). CAS PubMed Google ...
Can Knowledge From Treating Chronic Myeloid Leukemia Inform Therapy of EGFR-Mutant Lung Adenocarcinoma? Robert Peter Gale, MD, PhD Viewpoint Clinical Review & Education Children’s Oncology Group Pediatric Cancer Survivorship Guidelines Anna DeVine, RN, BSN, CPN, CPHON; et al. Review has active ...
对于EGFR突变型晚期NSCLC靶向治疗寡进展的患者,适应性治疗可以选择局部治疗或小分子激酶抑制剂的抗血管生成治疗。针对驱动基因阴性的晚期NSCLC一线含铂双药联合PD-1/PD-L1单抗治疗后寡进展患者的适应性治疗目前证据级别不高,不再赘述。 3.3.2 寡残留 鉴于EGFR突变型...
Randomized phase Ⅲ trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm). J Clin Oncol, 2021, 39(15 Suppl): 463s. 17. ...
Anlotinib combined with icotinib was effective and well-tolerated as a first-line treatment option for EGFR mutation-positive advanced NSCLC with or without concurrent mutations. Trial registration ClinicalTrials.gov identifier: NCT03736837.Background Non-small cell lung cancer (NSCLC), the leading caus...